Used in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity. It functions as a tyrosine kinase inhibitor, targeting BCR-ABL fusion protein and other kinases involved in cancer cell proliferation and survival. Also investigated for potential use in solid tumors and resistant cancer cases due to its broad kinase inhibition profile. Administered orally, it helps reduce tumor burden and improve patient survival in targeted therapy regimens.